Indoco Grows In Q3 With Domestic Boost
As Company Prepares To Double Capacity Going Ahead
Indoco has seen growth in Q3 FY22 based on the performance of its domestic business. Though the company hasn’t seen growth in its international segment, Indoco management says the firm is on track to perform better in the next quarter.
You may also be interested in...
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.
Cipla has partnered with mAbxience to supply oncology and respiratory-related biosimilars on the WHO model list of essential medicines to South Africa.
British Columbia has added three new biosimilar versions of the anti-clotting drug enoxaparin to PharmaCare, including Redesca, Noromby and Inclunox. The move comes after the Canadian province recently included additional biosimilars in its switching program.